Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA

NCT00637663 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: Entecavir
DRUG: Lamivudine

Sponsor

Pusan National University Hospital

Collaborators

[object Object]